Gyre Therapeutics (GYRE) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kamada (KMDA) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 14.7% versus a loss of 44.2%. Over five years, KMDA leads with a +22.7% price change compared with -77.5% for GYRE. Gyre Therapeutics is the larger company by market cap ($460.8 million vs $446.8 million), about 1.0 times the size, while Kamada is growing revenue faster (+12.1% vs +10.2%).
On valuation, Kamada trades at a lower forward P/E (13.3x vs 70.2x for Gyre Therapeutics). Kamada pays a dividend yielding 7.24%, while Gyre Therapeutics does not currently pay one. Kamada converts more of its revenue into profit, with a net margin of 11.2% versus 8.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | KMDA |
|---|---|---|
| Share price | $4.21 | $7.74 |
| Market cap | $460.79M | $446.85M |
| 1-day change | -6.86% | -1.15% |
| YTD return | -40.37% | +9.63% |
| 1-year return | -44.24% | +14.67% |
| 5-year return | -77.55% | +22.66% |
| P/E ratio (TTM) | — | 20.37 |
| Forward P/E | 70.17 | 13.34 |
| EPS (TTM) | $-0.31 | $0.38 |
| Dividend yield | 0.00% | 7.24% |
| Annual dividend | $0.00 | $0.56 |
| Revenue (latest FY) | $116.59M | $180.46M |
| Revenue growth (YoY) | +10.24% | +12.12% |
| Net income (latest FY) | $9.88M | $20.20M |
| Gross margin | 95.35% | 42.34% |
| Operating margin | 9.85% | 14.54% |
| Net margin | 8.47% | 11.19% |
| 52-week high | $9.14 | $9.35 |
| 52-week low | $3.97 | $6.63 |
| Distance from 52-week high | -53.94% | -17.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +343.47% | +77.65% |
| Average volume | 181.04K | 121.87K |
| Shares outstanding | 109.45M | 57.73M |
| Employees | 625 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed GYRE by 58.9 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
GYRE vs KMDA FAQ
Which is bigger, Gyre Therapeutics or Kamada?
Gyre Therapeutics (GYRE) is larger, with a market capitalization of $460.79M compared with $446.85M for Kamada (KMDA).
Which stock has performed better over the past year, GYRE or KMDA?
KMDA returned +14.67% over the past 12 months, compared with -44.24% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Gyre Therapeutics or Kamada?
Kamada pays a dividend yielding 7.24%, while Gyre Therapeutics does not currently pay a regular dividend.
Are Gyre Therapeutics and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.